515 related articles for article (PubMed ID: 24162260)
21. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.
Stopeck AT; Fizazi K; Body JJ; Brown JE; Carducci M; Diel I; Fujiwara Y; Martín M; Paterson A; Tonkin K; Shore N; Sieber P; Kueppers F; Karsh L; Yardley D; Wang H; Maniar T; Arellano J; Braun A
Support Care Cancer; 2016 Jan; 24(1):447-455. PubMed ID: 26335402
[TBL] [Abstract][Full Text] [Related]
22. Safety of Denosumab Versus Zoledronic Acid in Patients with Bone Metastases: A Meta-Analysis of Randomized Controlled Trials.
Chen F; Pu F
Oncol Res Treat; 2016; 39(7-8):453-9. PubMed ID: 27487236
[TBL] [Abstract][Full Text] [Related]
23. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
Raje N; Terpos E; Willenbacher W; Shimizu K; García-Sanz R; Durie B; Legieć W; Krejčí M; Laribi K; Zhu L; Cheng P; Warner D; Roodman GD
Lancet Oncol; 2018 Mar; 19(3):370-381. PubMed ID: 29429912
[TBL] [Abstract][Full Text] [Related]
24. Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance).
Shapiro CL; Moriarty JP; Dusetzina S; Himelstein AL; Foster JC; Grubbs SS; Novotny PJ; Borah BJ
J Clin Oncol; 2017 Dec; 35(35):3949-3955. PubMed ID: 29023215
[TBL] [Abstract][Full Text] [Related]
25. The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease.
Diel IJ; Body JJ; Stopeck AT; Vadhan-Raj S; Spencer A; Steger G; von Moos R; Goldwasser F; Feng A; Braun A
Eur J Cancer; 2015 Jul; 51(11):1467-75. PubMed ID: 25976743
[TBL] [Abstract][Full Text] [Related]
26. Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study-Asian Subgroup Analysis.
Huang SY; Yoon SS; Shimizu K; Chng WJ; Chang CS; Wong RS; Gao S; Wang Y; Gordon SW; Glennane A; Min CK
Adv Ther; 2020 Jul; 37(7):3404-3416. PubMed ID: 32524500
[TBL] [Abstract][Full Text] [Related]
27. Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid.
Martin M; Bell R; Bourgeois H; Brufsky A; Diel I; Eniu A; Fallowfield L; Fujiwara Y; Jassem J; Paterson AH; Ritchie D; Steger GG; Stopeck A; Vogel C; Fan M; Jiang Q; Chung K; Dansey R; Braun A
Clin Cancer Res; 2012 Sep; 18(17):4841-9. PubMed ID: 22893628
[TBL] [Abstract][Full Text] [Related]
28. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
James N; Pirrie S; Pope A; Barton D; Andronis L; Goranitis I; Collins S; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Russell M; Billingham L
Health Technol Assess; 2016 Jul; 20(53):1-288. PubMed ID: 27434595
[TBL] [Abstract][Full Text] [Related]
29. Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases.
von Moos R; Body JJ; Egerdie B; Stopeck A; Brown J; Fallowfield L; Patrick DL; Cleeland C; Damyanov D; Palazzo FS; Marx G; Zhou Y; Braun A; Balakumaran A; Qian Y
Support Care Cancer; 2016 Mar; 24(3):1327-37. PubMed ID: 26329397
[TBL] [Abstract][Full Text] [Related]
30. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
McKeage K; Plosker GL
Pharmacoeconomics; 2008; 26(3):251-68. PubMed ID: 18282018
[TBL] [Abstract][Full Text] [Related]
31. Which Bone-Modifying Agent is Associated with Better Outcomes in Patients with Skeletal Metastases from Lung Cancer? A Systematic Review and Network Meta-analysis.
Bozzo A; Deng J; Abbas U; Bhasin R; Deodat M; Wariach S; Sanger S; Axelrod D; Masrouha K; Turcotte R; Wilson D; Ghert M
Clin Orthop Relat Res; 2021 Sep; 479(9):2047-2057. PubMed ID: 33835092
[TBL] [Abstract][Full Text] [Related]
32. A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America.
Raje N; Roodman GD; Willenbacher W; Shimizu K; García-Sanz R; Terpos E; Kennedy L; Sabatelli L; Intorcia M; Hechmati G
J Med Econ; 2018 May; 21(5):525-536. PubMed ID: 29480139
[TBL] [Abstract][Full Text] [Related]
33. [Markers of bone metabolism in multiple myeloma patients switched from zoledronic acid to denosumab].
Tatekoshi A; Sato T; Ibata S; Hashimoto A; Kamihara Y; Horiguchi H; Ono K; Takada K; Iyama S; Takimoto R; Kobune M; Kato J
Rinsho Ketsueki; 2014 Nov; 55(11):2271-6. PubMed ID: 25501406
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer.
Snedecor SJ; Carter JA; Kaura S; Botteman MF
Clin Ther; 2012 Jun; 34(6):1334-49. PubMed ID: 22578308
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic.
Cristino J; Finek J; Jandova P; Kolek M; Pásztor B; Giannopoulou C; Qian Y; Brezina T; Lothgren M
J Med Econ; 2017 Aug; 20(8):799-812. PubMed ID: 28485692
[TBL] [Abstract][Full Text] [Related]
36. Denosumab and bone metastases. No better than a bisphosphonate.
Prescrire Int; 2012 Sep; 21(130):204-6. PubMed ID: 23016249
[TBL] [Abstract][Full Text] [Related]
37. Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours.
Ford J; Cummins E; Sharma P; Elders A; Stewart F; Johnston R; Royle P; Jones R; Mulatero C; Todd R; Mowatt G
Health Technol Assess; 2013 Jul; 17(29):1-386. PubMed ID: 23870108
[TBL] [Abstract][Full Text] [Related]
38. Patients' preferences for bone metastases treatments in France, Germany and the United Kingdom.
Hechmati G; Hauber AB; Arellano J; Mohamed AF; Qian Y; Gatta F; Haynes I; Bahl A; von Moos R; Body JJ
Support Care Cancer; 2015 Jan; 23(1):21-8. PubMed ID: 24939674
[TBL] [Abstract][Full Text] [Related]
39. Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials.
Jiang L; Cui X; Ma H; Tang X
J Orthop Surg Res; 2021 Jun; 16(1):400. PubMed ID: 34158101
[TBL] [Abstract][Full Text] [Related]
40. Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial.
Raje N; Vadhan-Raj S; Willenbacher W; Terpos E; Hungria V; Spencer A; Alexeeva Y; Facon T; Stewart AK; Feng A; Braun A; Balakumaran A; Roodman GD
Blood Cancer J; 2016 Jan; 6(1):e378. PubMed ID: 26745852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
